178209-29-5

Usage

Uses

Used in Pharmaceutical Research:
5H-Cyclopenta[b]pyridin-3-amine,6,7-dihydro-(9CI) is used as a building block for the synthesis of biologically active molecules, contributing to the development of new pharmaceutical agents.
Used in Drug Development for Neurological and Psychiatric Disorders:
In the field of medicinal chemistry, 5H-Cyclopenta[b]pyridin-3-amine,6,7-dihydro-(9CI) is used as a potential drug target for the treatment of neurological and psychiatric disorders, due to its ability to interact with specific receptors and enzymes in the brain.
Used in Organic Synthesis:
5H-Cyclopenta[b]pyridin-3-amine,6,7-dihydro-(9CI) is also utilized in the field of organic synthesis, where it may serve as a key intermediate in the creation of more complex organic molecules with potential applications in various industries.

InChI:InChI=1/C8H10N2/c9-7-4-6-2-1-3-8(6)10-5-7/h4-5H,1-3,9H2

Upstream product

• 84531-36-2 6,7-dihydro-3-nitro-5H-cyclopentapyridine 

Downstream Products

• 1421429-82-4 phenyl 6,7-dihydro-5H-cyclopenta[b]pyridin-3-ylcarbamate 

Relevant academic research and scientific papers

Substituted Bicyclic Aromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds, and a method of using these compounds in the treatment and/or inhibition of pain and further diseases and/or disorders mediated at least in part via the vanilloid receptor 1 (VR1/TRPV1).

SUBSTITUTED BICYCLIC AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Synthesis and structure-activity relationships of fused imidazopyridines: A new series of benzodiazepine receptor ligands

2-Arylimidazo[4,5-c]quinolines and analogous fused imidazopyridines were synthesized and evaluated as benzodiazepine receptor ligands. Affinity to the receptors was greatly affected by the bulkiness of the aryl group at the 2- position, compared to the pyrazoloquinolines such as CGS-9896. Derivatives with an isoxazole moiety at the 2-position showed high binding affinity and in vivo activity. In the imidazo[4,5-c]quinoline series, substitution at the 6-position decreased or abolished activity. Most derivatives with an unsubstituted isoxazolyl group showed antagonist or inverse agonist activity except for the 7-halo analogues, which exhibited agonist activity. On the other hand, 5-methylisoxazol-3-yl or 3-methylisoxazol-5-yl derivatives generally exhibited agonist activity. A similar substitution effect on the isoxazole moiety was observed in the imidazopyridines fused with a nonaromatic ring. From the detailed pharmacological evaluation, S-8510, 2- (3-isoxazolyl)-3,6,7,9-tetrahydroimidazo[4,5-d]pyrano[4,3-b]pyridine monophosphate, possessing weak inverse agonist activity was selected as a therapeutic candidate for the treatment of some symptoms of senile dementia.